Recursion Pharmaceuticals, Inc. · NASDAQ:RXRX
Recursion Pharmaceuticals — Investor Presentation (November 2021)
45 slides from Recursion Pharmaceuticals's investor presentation, Nov 10, 2021
Slide 1: Decoding Biology To Radically Improve Lives
Decoding Biology To Radically Improve Lives 9g Recursion
Slide 2: Forward-looking statements
This presentation and any accompanying discussion or documents may contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These forward-looking statements are based on our current expectations, estimates and
Slide 3: Trademarks notice
3 Trademarks are the property of their respective owners and used for informational purposes only.
Slide 4: About 90% of clinical trials fail; 14 years and $2B per approval
0 20 40 60 80 100 120 140 160 180 200 0 5 10 15 20 25 30 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 4 Source: based on EvaluatePharma. Analysis is not inflation-adjusted. Analysis is not restricted to novel molecules, though it does exclude generics. Cu
Slide 5: Why have we not seen the same scale of improvements in drug discovery?
Why have we not seen the same scale of improvements in drug discovery and development efficiency?
Slide 6: Because biology is massively complex
Because biology is massively complex
Slide 7: Exponential improvements in tools and technology converging
AI Expert Systems given way to Modern AI Automation Automation tools enable massive scale Storage 1M-Fold Decrease In Costs over 40 years Compute 1M-Fold Increase in Compute over 40 years Bio Tools Tools like CRISPR allow CONTROL of Biology Exponential improvements in tools and technology are conver
Slide 8: Platform scale: experiments, data, inferred relationships
8 ~95M Proprietary experiments in human cells conducted in our own laboratories 11PB+ At >11 petabytes, one of the largest proprietary biological and chemical datasets ~200B Inferred relationships between human genes, chemical compounds and more using our Map of biology 38 Human cell types onboarded
Slide 9: Recursion Operating System
An integrated, multi-faceted system for generating, analyzing, and deriving insight from massive biological and chemical datasets to industrialize drug discovery. It is composed of: • Infrastructure Layer • Recursion Data Universe • Recursion Map …and held together by our People and Culture Enabling
Slide 10: In-house software and automated laboratories
Recursion in-house software to design, manage and execute experiments Execute up to 1.7 million experiments each week in highly automated laboratories Generate high-dimensional data including phenomics, proteomics, transcriptomics, and more at scale 10
Slide 11: Data flux and digital chemistry tools
We have more data flux to the cloud than the firehose Over 11 PB of data served to scientists using Recursion software to generate insights In-house digital chemistry tools to in silico screen 12 billion molecules 11 Trademarks are the property of their respective owners and used for informational p
Slide 12: Empirical data generation to novel insights
Empirical Data Generation Advanced Computation Program Acceleration Novel Insights 12
Slide 13: Failing faster and earlier, spending less, going faster
Data shown is the average of all our programs since late 2017. All industry data adapted from Paul, et al. Nature Reviews Drug Discovery. (2010) 9, 203–214 Failing faster and earlier to … … spend less … … and go faster 13
Slide 14: Breadth of active research and development programs
The power of the Recursion OS is demonstrated by the scale and breadth of active research and development programs ‘Stage of Development CLINICAL PRECLINICAL LATE DISCOVERY EARLY DISCOVERY © NeUROINFLAMMATION (©yrokine combo: est 136) (O FAMLiAL ADENOMATOUS PoLYPOSIS (APC, eat 50K) © tmmune cHecKPom
Slide 15: Inferring biological relationships across therapeutic areas
Immunology Using ~95M proprietary experiments, we can algorithmically infer ~200B biological relationships across the human genome, 100s of thousands of compounds and soluble factors to explore many therapeutic areas for novel targets, compounds and mechanisms: NeuroscienceOncology Similar Opposite
Slide 16: Oncology: pathways cluster independently
Shown below are therapeutic area specific subsets of the thousands of genetic knockouts, compounds, and soluble factors profiled by the Recursion OS Oncology Multiple oncology pathways cluster independently demonstrating ability to identify known biology, including negative regulators in the same pa
Slide 17: Oncology: novel target gene inferred
Shown below are therapeutic area specific subsets of the thousands of genetic knockouts, compounds, and soluble factors profiled by the Recursion OS Oncology Knockout of novel gene is inferred to be similar to PI3K gene family, presenting a potential novel target gene RAS family negative regulators
Slide 18: Neuroscience: mitochondrial and autophagy genes cluster
Shown below are therapeutic area specific subsets of the thousands of genetic knockouts, compounds, and soluble factors profiled by the Recursion OS Neuroscience Gene knockout of mitochondrial and autophagy genes, highly relevant in neurological disorders, cluster as expected Mitochondrial complex g
Slide 19: Neuroscience: compounds with distinct mechanisms of action
Shown below are therapeutic area specific subsets of the thousands of genetic knockouts, compounds, and soluble factors profiled by the Recursion OS Neuroscience Similar Opposite Compounds with three distinct Mechanisms of Action (MoAs) are potential starting points for discovery efforts Mitochondri
Slide 20: Immunology: IL6 relationships
Immunology Shown below are therapeutic area specific subsets of the thousands of genetic knockouts, compounds, and soluble factors profiled by the Recursion OS Knockout of IL6 gene family and dosing of cells with IL6 show expected opposite relationship Similar Opposite Known JAK inhibitors IL6 gene
Slide 21: Immunology: novel chemical series
Shown below are therapeutic area specific subsets of the thousands of genetic knockouts, compounds, and soluble factors profiled by the Recursion OS Immunology A novel chemical series similar to IL6 gene knockout and opposite to IL6 soluble factor dosing present a starting point for a discovery effo
Slide 22: Pipeline and partnership strategy; fibrosis collaboration
Internal Pipeline - Rare Genetic Diseases Asset Sales / Licenses / Commercialization Partnership strategy • Enterprise scale contracts • Add knowledge to our growing map of biology -- Capital Efficient Disease Opportunities Discovery Partnership Contracts -- Large Therapeutic Areas Commercialization
Slide 23: Forward program growth
Forward program growth Significant program growth • Growing economic opportunity • Reduction of binary risks (1) ‘Unique Perturbations’ refers to the number of gene, soluble factor, cell and/or compound combinations physically explored. (2) Includes approximately 500,000 compounds from Bayer’s propr
Slide 24: Pipeline comparison with industry peers
Company Early Discovery – Preclinical Clinical / Commercial Assets 13 18 10 18 11 3 7 12 7 (multiple through collaboration) 1 2 52 4 Pipeline data from company websites as of 11/08/2021. Trademarks are the property of their respective owners and used for informational and educational purposes only.
Slide 25: Trademarks are the property of their respective owners and used for informational purposes only.
25 Trademarks are the property of their respective owners and used for informational purposes only. Analysis as of April 2021.
Slide 26: Team experience and employee split
26 Team ExperienceFull-time Employee Split Biology, Chemistry & Development ~40% Data Science, Software Engineering & Automation ~35% BD, Product, Administration, Legal, IP, etc. ~25% Advanced degrees (Ph.D. or M.D.) Employees today Team Credentials ~25% 330+ Gender: % Women ~45% ~45% Below VP VP an
Slide 27: Executive team and Board of Directors
27 Board of Directors TINA LARSON President & COO MASON VICTORS Chief Product Officer RON ALFA, MD/PHD SVP of Research Executive Team CHRIS GIBSON, PHD Co-Founder & CEO DEAN LI, MD/PHD Recursion Co-founder, President of Merck Research Labs ZAVAIN DAR Partner, Lux Capital ZACHARY BOGUE, JD Partner, D
Slide 28: Impact
28 Impact
Slide 29: Partnerships, people, programs and capabilities
Partnerships • Advancing multiple simultaneous discovery programs with Bayer in fibrosis • Exploring enterprise-scale partnerships People • Grew from 217 employees at IPO to >330 today • Opened Montreal Office and hired multiple machine learning research scientists 29 Programs • Fast Track Designati
Slide 30: Industrialize drug discovery broadly across biology
Recursion OS - Industrialize small molecule drug discovery broadly across biology Other Modalities including large molecules and RNA therapeutics Diagnostics Finance Animal Health, Smart Agriculture 30
Slide 31: REC-4881 in familial adenomatous polyposis
Disease Overview: • Autosomal dominantly inherited rare tumor syndrome caused by mutations in APC gene affecting ~50,000 patients in US and EU5 Expected Milestone: • First patient enrolled in a phase 2 randomized, double-blind, placebo- controlled trial in the first half of 2022 Summary and differen
Slide 32: Planned Phase 2 trial in classical FAP
Eligibility: ≥ 18 years of age with clinical diagnosis of FAP with more than 100 polyps prior to colectomy or APC gene mutation REC-4881 Dose A REC-4881 Dose B Placebo R 2:2:1 Responder REC-4881 or 24 Week Follow-up Non-Responder REC-4881 or Standard of Care Placebo REC-4881 or Standard of Care 45 d
Slide 33: REC-994 in cerebral cavernous malformation
33 REC-994 reduces lesion number in chronic mouse models of CCM Disease Overview: • Autosomal dominantly inherited neurovascular disease caused by mutations in CCM1, CCM2, or CCM3 genes affecting approximately 360,000 patients in US and EU5 Expected Milestone: • First patient enrolled in a Phase 2 d
Slide 34: Planned Phase 2 trial in symptomatic CCM
≤ 8 weeks 52 weeks 4 weeks REC-994 Low Dose Placebo Eligibility: ≥ 18 years of age with anatomic CCM lesions demonstrated by MRI Follow-up PeriodREC-994 High DoseR 1:1:1 Planned Phase 2 Clinical Trial: Efficacy and Safety in Symptomatic CCM Patients 34
Slide 35: REC-2282 in NF2 meningiomas
35 REC-2282 prevents growth of human vestibular schwannoma and meningioma tumor grafts in mouse studies Disease Overview: • Autosomal dominantly inherited rare tumor syndrome caused by mutations in NF2 gene • 33,000 patients per year in US and EU5 affected by both inherited and sporadic meningiomas
Slide 36: Adaptive Phase 2/3 trial in meningioma
Phase 2 Phase 3 REC-2282 Placebo Eligibility: ≥ 12 years of age with progressive NF2-mutated meningiomas R 2:1 Adaptive Phase 2/3 Trial to Evaluate the Efficacy and Safety in Meningioma Patients R 1:1 REC-2282 40 mg REC-2282 60 mg Interim Analysis Progression 36
Slide 37: REC-3599 in GM2 gangliosidosis
37 REC-3599 reduces autofluorescence substrate accumulation and GM2 aggregates in GM2 patient-derived fibroblasts Disease Overview: • Pediatric lysosomal storage disease caused by mutations in HEXA or HEXB genes affecting more than 400 patients worldwide resulting in neurological decline and death i
Slide 38: Planned Phase 2 trial in infantile GM2 gangliosidosis
4 weeks 52 weeks 4 weeks Eligibility: Infants with documented diagnosis of infantile GM2 gangliosidosis Follow-up PeriodREC-3599 8 weeks REC-3599 Dose Escalation Planned Phase 2 Clinical Trial to Evaluate the Efficacy and Safety in Infantile GM2 Gangliosidosis 38
Slide 39: Preclinical and discovery programs
C. difficile Colitis (REC-3964) Current status: preclinical • New chemical entity with potential to be orally active, gut-biased, C. difficile toxin inhibitors via glycosyl transferase inhibition. • C. difficile affects up to 730k patients annually in the US and EU5 • IND-enabling studies underway L
Slide 40: C. difficile colitis (REC-3964)
40 C. difficile-infected model hamsters treated with REC-163964 survive longer than vehicle-treated animals Disease Overview: • Infectious disease caused by Clostridium difficile affecting more than 730,000 patients per year in the US and EU5 with hallmarks including severe diarrhea, colitis, and ri
Slide 41: Immune checkpoint resistance in STK11-mutant NSCLC
41 Disease Overview: • STK11 is a tumor suppressor mutated in a variety of cancers • Mutations in STK11 have been shown to underlie resistance of cancers to immune checkpoint inhibitors, especially in non-small cell lung cancer (NSCLC) • STK11 mutations characterize approximately 30,000 cases of met
Slide 42: Neuroinflammation lead molecules
42 Disease Overview: • Neuroinflammation is a hallmark of diseases of the CNS, including neurodegenerative diseases with hallmark of microglial activation and secretion of proinflammatory cytokines such as TNFα, IL-6, IL-1ß, MCP-1 Summary and differentiation: • Orally bioavailable, CNS-penetrant sma
Slide 43: Cancer immunotherapy target: checkpoint resistance efficacy
43 Pheno-similar Pheno-opposite BIRC2 Target G ene A BIRC2 Target Gene A CT26: mouse colon carcinoma. REC-A was dosed PO, QD for 5 weeks. Anti-PD-1 was dosed IP, BIW for 5 weeks. 10 mice per group, dosing initiated when tumors reached ~ 80 mm3; * p<0.05 ** p<0.01 **** p<0.0001 Naïve mice Complete re
Slide 44: MYC inhibitors for solid and hematological malignancies
44 Disease Overview: • MYC regulates diverse cellular processes involved in oncogenesis • Gain-of-function alterations and amplifications in MYC have been identified in more than 50% of human cancers • MYC pathway activation is observed in tumors harboring alterations in diverse oncogenic mutations,
Slide 45: Charcot-Marie-Tooth type 2A (MFN2)
45 Disease Overview: • Rare, autosomal dominant, peripheral nerve disease caused by mutations in MFN2 estimated to affect approximately 15,000 patients in US & EU5 and leads to progressive muscle atrophy in the lower legs and hands Summary and differentiation: • Aim to discover and develop the first
Recursion Pharmaceuticals — Investor Presentation (November 2021) on 6ix